Energy metabolism defects in Huntington's disease and effects of coenzyme Q10

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes

MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366

Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?

Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 962

Mitochondrial defect in Huntington's disease caudate nucleus

Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758

Alternative excitotoxic hypotheses

Albin, R. L., & Greenamyre, J. T. (1992) · Neurology · doi:10.1212/wnl.42.4.733 · Cited by 574

Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates.

Brouillet, E., Hantraye, P., Ferrante, R. J., Dolan, R., Leroy‐Willig, A., Kowall, N. W., & Beal, M. F. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.7105 · Cited by 485

Rapid enzymatic measurement of blood lactate and pyruvate. Use and significance of metaphosphoric acid as a common precipitant.

Marbach, E. P., & Weil, M. H. (1967) · PubMed · Cited by 480

Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy

Jenkins, B. G., Koroshetz, W. J., Beal, M. F., & Rosen, B. R. (1993) · Neurology · doi:10.1212/wnl.43.12.2689 · Cited by 479

Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH

Burke, J. R., Enghild, J. J., Martin, M. E., Jou, Y., Myers, R., Roses, A. D., Vance, J. M., & Strittmatter, W. J. (1996) · Nature Medicine · doi:10.1038/nm0396-347 · Cited by 430

Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues

Strong, T. V., Tagle, D. A., Valdes, J. M., Elmer, L. W., Boehm, K., Swaroop, M., Kaatz, K. W., Collins, F. S., & Albin, R. L. (1993) · Nature Genetics · doi:10.1038/ng1193-259 · Cited by 417

Rapid Enzymatic Measurement of Blood Lactate and Pyruvate

Marbach, E. P., & Weil, M. H. (1967) · Clinical Chemistry · doi:10.1093/clinchem/13.4.314 · Cited by 396

Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats

Kumar, A., Sharma, N., Mishra, J., & Kalonia, H. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.03.042 · Cited by 40

A comprehensive perspective of Huntington’s disease and mitochondrial dysfunction

Dai, Y., Wang, H., Lian, A., Li, J., Zhao, G., Hu, S., & Li, B. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.03.001 · Cited by 40

Huntington's disease: progress and potential in the field

Stack, E. C., & Ferrante, R. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1933 · Cited by 39

Neuroprotective Effects of the α2-Adrenoceptor Antagonists, (+)-Efaroxan and (±)-Idazoxan, against Quinolinic Acid-Induced Lesions of the Rat Striatum

Martel, J.-C., Chopin, P., Colpaert, F. C., & Marien, M. R. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6942 · Cited by 39

Comparison of huntingtin proteolytic fragments in human lymphoblast cell lines and human brain

Toneff, T., Mende‐Mueller, L., Wu, Y. N., Hwang, S., Bundey, R. A., Thompson, L. M., Chesselet, M., & HOOK, V. Y. H. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00940.x · Cited by 38

Ubiquinol (reduced Coenzyme Q10) in patients with severe sepsis or septic shock: a randomized, double-blind, placebo-controlled, pilot trial

Donnino, M. W., Mortensen, S. J., Andersen, L. W., Chase, M., Berg, K. M., Balkema, J., Radhakrishnan, J., Gazmuri, R. J., Liu, X., & Cocchi, M. N. (2015) · Critical Care · doi:10.1186/s13054-015-0989-3 · Cited by 38

Molecular Mechanisms Underlying Muscle Wasting in Huntington’s Disease

Bozzi, M., & Sciandra, F. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218314 · Cited by 38

Cytochrome c oxidase isoform IV‐2 is involved in 3‐nitropropionic acid‐induced toxicity in striatal astrocytes

Singh, S., Misiak, M., Beyer, C., & Arnold, S. (2009) · Glia · doi:10.1002/glia.20864 · Cited by 36

Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease

Hickey, M. A., Zhu, C., Medvedeva, V. P., Franich, N. R., Levine, M. S., & Chesselet, M. (2011) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2011.10.007 · Cited by 35

Improvement of mitochondrial NAD+/FAD+-linked state-3 respiration by caffeine attenuates quinolinic acid induced motor impairment in rats: Implications in Huntington's disease

Mishra, J., & Kumar, A. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.07.006 · Cited by 35

Coenzyme Q and protein/lipid oxidation in a BSE-infected transgenic mouse model

Martin, S. F., Burón, I., Espinosa, J. C., Castilla, J., Villalba, J. M., & Torres, J. M. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.03.005 · Cited by 35

Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin

Naia, L., Ribeiro, M., Rodrigues, J., Duarte, A. I., Lopes, C., Rosenstock, T. R., Hayden, M. R., & Rego, A. C. (2016) · Neuropeptides · doi:10.1016/j.npep.2016.01.009 · Cited by 35

Metabolism in Huntington’s disease: a major contributor to pathology

Singh, A., & Agrawal, N. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00844-y · Cited by 34

Therapeutic approaches to preventing cell death in Huntington disease

Kaplan, A. R., & Stockwell, B. R. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.004 · Cited by 32

The Effects of YAP and Its Related Mechanisms in Central Nervous System Diseases

Jin, J., Zhao, X., Fu, H., & Gao, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00595 · Cited by 36

Boosting mitochondrial health to counteract neurodegeneration

Burtscher, J., Romani, M., Bernardo, G., Popa, T., Ziviani, E., Hummel, F. C., Sorrentino, V., & Millet, G. P. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102289 · Cited by 36

Novel therapeutic targets for Huntington’s disease

Hannan, A. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.639 · Cited by 32

Impaired performance of skeletal muscle in α‐glucosidase knockout mice

Hesselink, R. P., Gorselink, M., Schaart, G., Wagenmakers, A. J. M., Kamphoven, J. H. J., Reuser, A. J. J., Vusse, G. J., & Drost, M. R. (2002) · Muscle & Nerve · doi:10.1002/mus.10125 · Cited by 32

Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease

Chen, L., Horng, L., Wu, C.-L., Sung, H., & Wu, R.-T. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.019 · Cited by 31

Coenzyme Q10 serum levels in Huntington’s disease

Andrich, J., Carsten Saft, C., Gerlach, M., Schneider, B., Arz, A., Kuhn, W., & Müller, T. (2004) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0579-5_13 · Cited by 31

Mitochondrial functional alterations in relation to pathophysiology of Huntington’s disease

Pandey, M., Mohanakumar, K. P., & Rajamma, U. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9288-5 · Cited by 30

Evaluation of antioxidant systems (coenzyme Q10 and total antioxidant capacity) in morbid obesity before and after biliopancreatic diversion

Mancini, A., Leone, E., Festa, R., Grande, G., Donna, V. D., Marinis, L. D., Pontecorvi, A., Tacchino, R. M., Littarru, G. P., Silvestrini, A., et al. (2008) · Metabolism · doi:10.1016/j.metabol.2008.05.007 · Cited by 30

Energy-modulating vitamins – a new combinatorial therapy prevents cancer cachexia in rat mammary carcinoma

Perumal, S. S., Shanthi, P., & Sachdanandam, P. (2005) · British Journal Of Nutrition · doi:10.1079/bjn20051439 · Cited by 30

Coenzyme Q10 and neuropsychiatric and neurological disorders: relevance for schizophrenia

Maguire, Á., Hargreaves, A., & Gill, M. (2018) · Nutritional Neuroscience · doi:10.1080/1028415x.2018.1556481 · Cited by 30

Emerging chemotherapeutic strategies for Huntington’s disease

Ryu, H., & Ferrante, R. J. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.345 · Cited by 30

Chorea and its disorders

Higgins, D. S. (2001) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70041-4 · Cited by 29

High-Dose Glycine Treatment of Refractory Obsessive-Compulsive Disorder and Body Dysmorphic Disorder in a 5-Year Period

Cleveland, W. L., DeLaPaz, R. L., Fawwaz, R. A., & Challop, R. S. (2009) · Neural Plasticity · doi:10.1155/2009/768398 · Cited by 30

Metabolic Consequences of the CytochromecOxidase Deficiency in Brain of Copper‐Deficient MovbrMice

Kunz, W. S., Kuznetsov, A. V., Clark, J. F., Tracey, I., & Elger, C. E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.721580.x · Cited by 28

A cue to queue for CoQ?

Shults, C. W., & Schapira, A. H. V. (2001) · Neurology · doi:10.1212/wnl.57.3.375 · Cited by 28

CPEB alteration and aberrant transcriptome-polyadenylation lead to a treatable SLC19A3 deficiency in Huntington’s disease

Picó, S., Parras, A., Santos‐Galindo, M., Pose‐Utrilla, J., Castro, M., Fraga, E., Hernández, I. H., Elorza, A., Anta, H., Wang, N., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe7104 · Cited by 28

Coenzyme Q10 and its effects in the treatment of neurodegenerative diseases

dos Santos, G. C., Antunes, L. M. G., dos Santos, A. C., & Bianchi, M. D. L. P. (2009) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502009000400002 · Cited by 28

Proteomic changes in the brains of Huntington's disease mouse models reflect pathology and implicate mitochondrial changes

Deschepper, M., Hoogendoorn, B., Brooks, S. P., Dunnett, S. B., & Jones, L. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.01.012 · Cited by 27

Assessment of In Vitro and In Vivo Mitochondrial Function in Friedreich's Ataxia and Huntington's Disease

Schapira, A. H. V., & Lodi, R. (2004) · Humana Press eBooks · doi:10.1385/1-59259-804-8:293 · Cited by 26

Mitochondrial function in Huntington's disease: Clues for pathogenesis and prospects for treatment

Schapira, A. H. V. (1997) · Annals of Neurology · doi:10.1002/ana.410410203 · Cited by 27

Differential effects of the Huntington's disease CAG mutation in striatum and cerebellum are quantitative not qualitative

Fossale, E., Seong, I. S., Coser, K. R., Shioda, T., Kohane, I. S., Wheeler, V. C., Gusella, J. F., MacDonald, M. E., & Lee, J. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr355 · Cited by 25

Proton Magnetic Resonance Spectroscopy in Kennedy Syndrome

Karitzky, J., Block, W., Mellies, J. K., Träber, F., Sperfeld, A. D., Schild, H. H., Haller, P., & Ludolph, A. C. (1999) · Archives of Neurology · doi:10.1001/archneur.56.12.1465 · Cited by 26

The "new" mitochondrial disorders

Schapira, A. H. V. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.2.144 · Cited by 26

Huntington's disease

Scherder, E., & Statema, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61990-3 · Cited by 26

Integrated multi-omics analysis of Huntington disease identifies pathways that modulate protein aggregation

Pradhan, S. S., Manohar, T. S., Saiswaroop, R., Bhagavatham, S. K. S., Pulukool, S. K., Rathnakumar, S., Kanikaram, S. P., Dandamudi, R. B., Pargaonkar, A., Joseph, P., et al. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049492 · Cited by 25

Involvement of Coenzyme Q10 in Various Neurodegenerative and Psychiatric Diseases

Ebrahimi, A., Kamyab, A., Hosseini, S., Ebrahimi, S., & Ashkani‐Esfahani, S. (2023) · Biochemistry Research International · doi:10.1155/2023/5510874 · Cited by 29

MR imaging and spectroscopy in juvenile Huntington disease

Schapiro, M. B., Cecil, K. M., Doescher, J. S., Kiefer, A., & Jones, B. V. (2004) · Pediatric Radiology · doi:10.1007/s00247-004-1159-y · Cited by 25

Selective striatal mtDNA depletion in end-stage Huntington's disease R6/2 mice

Hering, T., Birth, N., Taanman, J., & Orth, M. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.02.004 · Cited by 23

Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats

Kalonia, H., Kumar, P., & Kumar, A. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.02.031 · Cited by 22

Gene transfer of human heme oxygenase into coronary endothelial cells potentially promotes angiogenesis

Deramaudt, B. M. J. ‐., Braunstein, S. E., Rémy, P., & Abraham, N. G. (1998) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19980101)68:1 · Cited by 215

Indoleamine 2,3-dioxygenase as a novel therapeutic target for Huntington’s disease

Boros, F. A., Klivènyi, P., Toldi, J., & Vécsei, L. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1549231 · Cited by 20

Functional interactions within striatal microcircuit in animal models of Huntington's disease

Ghiglieri, V., Bagetta, V., Calabresi, P., & Picconi, B. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.06.075 · Cited by 19

Brain region specificity of 3-nitropropionic acid-induced vulnerability of neurons involves cytochrome c oxidase

Singh, S., Misiak, M., Beyer, C., & Arnold, S. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.06.008 · Cited by 21

Bioenergetics in fibroblasts of patients with Huntington disease are associated with age at onset

Gardiner, S. L., Milanese, C., Boogaard, M. W., Buijsen, R. A. M., Hogenboom, M., Roos, R. A. C., Mastroberardino, P. G., van Roon‐Mom, W., & Aziz, N. A. (2018) · Neurology Genetics · doi:10.1212/nxg.0000000000000275 · Cited by 20

Molecular biology of Huntington's disease

McFarland, K. N., & Cha, J.-H. J. (2011) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52014-2.00003-3 · Cited by 21

Abnormal Weight and Body Mass Index in Children with Juvenile Huntington’s Disease

Tereshchenko, A., McHugh, M. A., Lee, J. K., Gonzalez‐Alegre, P., Crane, K., Dawson, J. D., & Nopoulos, P. (2015) · Journal of Huntington s Disease · doi:10.3233/jhd-150152 · Cited by 20

A Longitudinal Motor Characterisation of the HdhQ111 Mouse Model of Huntington’s Disease

Yhnell, E., Dunnett, S. B., & Brooks, S. P. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160191 · Cited by 21

The Expanding Clinical Universe of Polyglutamine Disease

Huang, S., Zhu, S., Li, X., & Li, S. (2019) · The Neuroscientist · doi:10.1177/1073858418822993 · Cited by 20

Experimental Models of HD and Reflection on Therapeutic Strategies

Kim, J., Bordiuk, O. L., & Ferrante, R. J. (2011) · International review of neurobiology · doi:10.1016/b978-0-12-381328-2.00016-x · Cited by 20

Mitochondrial and metabolic-based protective strategies in Huntington’s disease: the case of creatine and coenzyme Q

Naia, L., Ribeiro, M. J., & Rego, A. C. (2011) · Reviews in the Neurosciences · doi:10.1515/rns.2011.060 · Cited by 19

Polyglutamine Disorders Including Huntington's Disease

Todi, S. V., Williams, A. J., & Paulson, H. L. (2007) · Elsevier eBooks · doi:10.1016/b978-012369509-3.50019-6 · Cited by 19

Future directions in research with presymptomatic individuals carrying the gene for Huntington’s disease

Georgiou‐Karistianis, N., Smith, E., Bradshaw, J. L., Chua, P. M.-L., Lloyd, J., Churchyard, A., & Chiu, E. (2002) · Brain Research Bulletin · doi:10.1016/s0361-9230(02)00877-8 · Cited by 19

Imaging in cell-based therapy for neurodegenerative diseases

Kirik, D., Breysse, N., Björklund, T., Besret, L., & Hantraye, P. (2005) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-005-1909-6 · Cited by 18

Toxin-induced mitochondrial dysfunction

Browne, S. E., & Beal, M. F. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)53010-5 · Cited by 17

Effects of aluminum chloride and coenzyme Q10 on the molecular structure of lipids and the morphology of the brain hippocampus cells

Saeed, A., Qusti, S. Y., Almarwani, R. H., Jambi, E. J., Alshammari, E. M., Gusty, N. F., & Balgoon, M. J. (2021) · RSC Advances · doi:10.1039/d1ra03786b · Cited by 16

Huntington's disease

Bonelli, R. M., & Beal, M. F. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52002-9.00030-9 · Cited by 16

Development of novel therapies for Huntington's disease: hope and challenge1

Qin, Z., Wang, J., & Gu, Z. (2005) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2005.00520.x · Cited by 16

NMR Spectroscopy-based Metabolomics of Drosophila Model of Huntington’s Disease Suggests Altered Cell Energetics

Singh, V. P., Sharma, R. K., Athilingam, T., Sinha, P., Sinha, N., & Thakur, A. K. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00491 · Cited by 15

Advances in Huntington’s disease: implications for experimental therapeutics

Feigin, A. (1998) · Current Opinion in Neurology · doi:10.1097/00019052-199808000-00012 · Cited by 15

Practical importance of neuroprotection in Parkinson's disease

Riederer, P. F., Gille, G., Müller, T., Przuntek, H., Reichmann, H., Rieß, O., Schwartz, A., Schwarz, J., & VOGT, T. M. (2002) · Journal of Neurology · doi:10.1007/s00415-002-1311-2 · Cited by 14

Molecular Biology of Huntington's Disease (HD) and HD-Like Disorders

Rubinsztein, D. C. (2003) · Elsevier eBooks · doi:10.1016/b978-012566652-7/50035-6 · Cited by 14

Mitochondrial Biology and the Identification of Biomarkers of Huntington’s Disease

Neueder, A., & Orth, M. (2020) · Neurodegenerative Disease Management · doi:10.2217/nmt-2019-0033 · Cited by 13

Lithium carbonate and coenzyme Q10 reduce cell death in a cell model of Machado-Joseph disease

Lopes‐Ramos, C. M., Pereira, T. C., Dogini, D. B., Gilioli, R., & Lopes‐Cendes, Í. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20165805 · Cited by 13

Evaluation of antioxidant systems in pituitary-adrenal axis diseases

Mancini, A., Leone, E., Silvestrini, A., Festa, R., Donna, V. D., Marinis, L. D., Pontecorvi, A., Littarru, G. P., & Meucci, E. (2009) · Pituitary · doi:10.1007/s11102-009-0213-z · Cited by 14

The Biochemistry of Creatine

Turner, C. E., & Gant, N. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-401688-0.00007-0 · Cited by 13

Age-Dependent Biphasic Changes in Ischemic Sensitivity in the Striatum of Huntington's Disease R6/2 Transgenic Mice

Klapstein, G. J., & Levine, M. S. (2004) · Journal of Neurophysiology · doi:10.1152/jn.00483.2004 · Cited by 11

Plasma 8-hydroxy-2′-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10

Biglan, K., for the Huntington Study Group Pre2CARE Investigators, Dorsey, E. R., Evans, R. V. V., Ross, C. A., Hersch, S. M., Shoulson, I., Matson, W. R., & Kieburtz, K. D. (2012) · Journal of Huntington s Disease · doi:10.3233/jhd-2012-120007 · Cited by 12

Functional neuroimaging: a physiological perspective

Lin, A. (2010) · Frontiers in Neuroenergetics · doi:10.3389/fnene.2010.00017 · Cited by 13

Prospects for redox-based therapy in neurodegenerative diseases

Friedlich, A. L., & Beal, M. F. (2000) · Neurotoxicity Research · doi:10.1007/bf03033796 · Cited by 12

Lactate: A Theranostic Biomarker for Metabolic Psychiatry?

Caddye, E., Pineau, J., Reyniers, J., Ronen, I., & Colasanti, A. (2023) · Antioxidants · doi:10.3390/antiox12091656 · Cited by 11

Non-Cell Autonomous and Epigenetic Mechanisms of Huntington’s Disease

Kim, C., Yousefian-Jazi, A., Choi, S.-H., Chang, I., Lee, J.-H., & Ryu, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212499 · Cited by 13

Discovering the Potential Value of Coenzyme Q10 as an Adjuvant Treatment in Patients With Depression

Majmasanaye, M., Mehrpooya, M., Amırı, H., & Eshraghi, A. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001845 · Cited by 11

The Impact of Coenzyme Q10 on Neurodegeneration: a Comprehensive Review

Kadian, M., Sharma, G., Pandita, S., Sharma, K., Shrivasatava, K., Saini, N., & Kumar, A. (2022) · Current Pharmacology Reports · doi:10.1007/s40495-021-00273-6 · Cited by 11

Mitochondrial DNA haplogroups do not influence the Huntington's disease phenotype

Mancuso, M., Kiferle, L., Petrozzi, L., Nesti, C., Rocchi, A., Ceravolo, R., Orsucci, D., Maluccio, M. R., Bonuccelli, U., Filosto, M., et al. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.08.013 · Cited by 11

Metabolic Shifts as the Hallmark of Most Common Diseases: The Quest for the Underlying Unity

Schwartz, L. H., Henry, M., Alfarouk, K. O., Reshkin, S. J., & Radman, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083972 · Cited by 10

Coenzyme Q10 Does Not Prevent Oral Dyskinesias Induced by Long-Term Haloperidol Treatment of Rats

Andreassen, O. A., Weber, C., & Jørgensen, H. A. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00118-5 · Cited by 10

Biomarkers for Huntington's disease

Wild, E. J., & Tabrizi, S. J. (2008) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2.1.47 · Cited by 10

Mitochondria in neurodegeneration

Beal, M. F. (2002) · Springer eBooks · doi:10.1007/978-2-8178-0929-8_3 · Cited by 10

Neurotrophic factor therapy — Keeping score

Hefti, F. F. (1997) · Nature Medicine · doi:10.1038/nm0597-497 · Cited by 10

Amendment of Altered Immune Response by Curcumin in Drosophila Model of Huntington’s Disease

Dhankhar, J., Shrivastava, A., & Agrawal, N. (2023) · Journal of Huntington s Disease · doi:10.3233/jhd-230595 · Cited by 9

A possible blood plasma biomarker for early-stage Alzheimer’s disease

Banack, S. A., Stark, A. C., & Cox, P. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267407 · Cited by 9

Physiopathologie de la maladie de Huntington : état des connaissances

Roze, E. F., Bétuing, S., Deyts, C., Vidailhet, M., & Caboche, J. (2008) · Revue Neurologique · doi:10.1016/j.neurol.2008.03.006 · Cited by 11

Effects of nerve and fibroblast growth factors on the production of nitric oxide in experimental model of Huntington's disease

Maksimovic, I., Jovanović, M., Maličević, Ž., Čolić, M. J., & Ninković, M. (2002) · Vojnosanitetski pregled · doi:10.2298/vsp0202119m · Cited by 9

Reducing huntingtin by immunotherapy delays disease progression in a mouse model of Huntington disease

Bartl, S., Xie, Y., Potluri, N., Kesineni, R., Hencak, K., Cengio, L. D., Balazs, K., Oueslati, A., Parth, M., Salhat, N., et al. (2023) · Neurobiology of Disease · doi:10.1016/j.nbd.2023.106376 · Cited by 8

Enfermedad de Huntington: una visión biomolecular

Leite, J. F. (2001) · Revista de Neurología · doi:10.33588/rn.3208.2000484 · Cited by 8

Huntington’s disease

Haskins, B. A., & Harrison, M. B. (2000) · Current Treatment Options in Neurology · doi:10.1007/s11940-000-0007-0 · Cited by 8

Novel Gene Therapeutic Strategies for Neurodegenerative Diseases

Maguire‐Zeiss, K. A., & Federoff, H. J. (2006) · Springer eBooks · doi:10.1007/3-540-27626-2_9 · Cited by 8

Mitochondrial Medicine: The Central Role of Cellular Energetic Depression and Mitochondria in Cell Pathophysiology

Seppet, E. K., Gizatullina, Z. Z., Trumbeckaitė, S., Zierz, S., Striggow, F., & Gellerich, F. N. (2007) · Wiley eBooks · doi:10.1002/9783527621095.ch15 · Cited by 8

CoenzymeQ10 localizations in model membranes. A Langmuir monolayer study

Nerdal, W., Nilsen, T. R. S., & Steinkopf, S. (2015) · Biophysical Chemistry · doi:10.1016/j.bpc.2015.09.003 · Cited by 7

Advanced drug delivery systems to treat Huntington’s disease: challenges and opportunities

Vishwas, S., Gulati, M., Khursheed, R., Arya, K. R., Singh, S. K., Jha, N. K., Prasher, P., Kumar, D., & Kumar, V. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99616-7.00005-0 · Cited by 8

Coenzyme Q10: A Review of Essential Functions

(2005) · The Internet Journal of Nutrition and Wellness · doi:10.5580/872 · Cited by 7

Doença de Huntington

Gil‐Mohapel, J., & Rego, A. C. (2001) · Revista Neurociências · doi:10.34024/rnc.2011.v19.8332 · Cited by 7

Coenzyme Q10 evaluation in pituitary‐adrenal axis disease: Preliminary data

Mancini, A., Bianchi, A., Fusco, A., Sacco, E., Leone, E., Tilaro, L., Porcelli, T., Giampietro, A., Principi, F., Marinis, L. D., et al. (2005) · BioFactors · doi:10.1002/biof.5520250123 · Cited by 7

Consequences of Mitochondrial Dysfunction in Huntington's Disease and Protection via Phosphorylation Pathways

Cunha‐Oliveira, T., Lusa, I., & Cristina, A. (2012) · InTech eBooks · doi:10.5772/32728 · Cited by 6

Protection of Malonate-Induced GABA But Not Dopamine Loss by GABA Transporter Blockade in Rat Striatum

Zeevalk, G. D., Manzino, L., & Sonsalla, P. K. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7917 · Cited by 7

Identification of regulated proteins by epigallocatechin gallate treatment in an ischemic cerebral cortex animal model: a proteomics approach

Park, D.-J., Kang, J.-B., & Koh, P. (2021) · Journal of Veterinary Medical Science · doi:10.1292/jvms.21-0089 · Cited by 6

Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease

Kašparová, S., Sumbalová, Z., Bystrický, P., Kucharská, J., Liptaj, T., Mlynárik, V., & Gvozdjáková, A. (2005) · Neurochemistry International · doi:10.1016/j.neuint.2005.09.002 · Cited by 65

Evidence for irnnairment of energy metabofism in vivo in Huntington's disease using localized 1H NMR spectroscopy

Jenkins, B. G., Koroshetz, W. J., Beal, M. F., & Rosen, B. R. (1993) · Neurology · doi:10.1212/wnl.43.12.2689 · Cited by 479

Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice

Smith, K. M., Matson, S., Matson, W. R., Cormier, K., Del Signore, S. J., Hagerty, S. W., Stack, E. C., Ryu, H., & Ferrante, R. J. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.03.004 · Cited by 127

A Gain of Function of the Huntington’s Disease and Amyotrophic Lateral Sclerosis-Associated Genetic Mutations May Be a Loss of Bioenergetics

Beal, M. F. (2001) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-662-04399-8_13 · Cited by 1

Coenzyme Q10 serum levels in Huntington’s disease

Andrich, J., Carsten Saft, C., Gerlach, M., Schneider, B., Arz, A., Kuhn, W., & Müller, T. (2004) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-0579-5_13 · Cited by 31